Affordable biosimilars can significantly reduce Indias rising healthcare costs and improve patient access to essential treatments. With supportive policies, India can lead globally in making high-quality therapies accessible to all.

Millions of Indian families struggle with rising healthcare costs, pushing 32-39 million people into poverty each year. With limited insurance coverage, many are forced to sell property or pawn valuables for treatment. Advanced biologics offer hope but come with high prices. However, affordable biosimilars, nearly identical to biologics, present a solution, reducing costs by 50-75%.

India, a leader in biosimilar production, has approved nearly 100 biosimilars, with more on the way. The government can further enhance guidelines and foster competitive pricing to ensure affordability. Integrating biosimilars into public health programs like Ayushman Bharat can further reduce costs and improve access. With the right policies, India can lead the global effort to make quality healthcare more accessible.

(Source:https://www.business-standard.com/economy/analysis/a-booster-shot-biosimilars-can-greatly-reduce-india-s-healthcare-costs-125031100691_1.html )